Kinarus Therapeutics Holding AG
SIX:KNRS
Kinarus Therapeutics Holding AG
SIX:KNRS
Price:
15
CHF
416 566.67%
Market Closed
Market Cap:
CHf19.5B
Balance Sheet
Balance Sheet Decomposition
Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG
Balance Sheet Decomposition is not available for
Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG
Balance Sheet
Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG
Currency: CHF
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
1
|
2
|
1
|
1
|
0
|
0
|
1
|
0
|
|
| Cash Equivalents |
1
|
2
|
1
|
1
|
0
|
0
|
1
|
0
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
3
|
3
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
12
|
0
|
|
| Goodwill |
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
12
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
6
N/A
|
3
-52%
|
2
-30%
|
2
-1%
|
0
-94%
|
0
+7%
|
13
+9 121%
|
0
-99%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
2
|
2
|
2
|
0
|
0
|
1
|
0
|
|
| Long-Term Debt |
0
|
0
|
0
|
1
|
0
|
0
|
3
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Liabilities |
2
N/A
|
2
-2%
|
2
-10%
|
3
+50%
|
0
-86%
|
1
+40%
|
1
+21%
|
0
-58%
|
|
| Equity | |||||||||
| Common Stock |
7
|
7
|
7
|
2
|
2
|
2
|
11
|
13
|
|
| Retained Earnings |
2
|
6
|
7
|
2
|
2
|
2
|
41
|
1
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
32
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
1
|
0
|
0
|
0
|
0
|
0
|
41
|
14
|
|
| Total Equity |
4
N/A
|
1
-74%
|
0
-67%
|
1
N/A
|
0
+53%
|
0
-56%
|
12
N/A
|
0
N/A
|
|
| Total Liabilities & Equity |
6
N/A
|
3
-52%
|
2
-30%
|
2
-1%
|
0
-94%
|
0
+7%
|
13
+9 121%
|
0
-99%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
173
|
180
|
181
|
181
|
164
|
164
|
1 135
|
1 302
|
|
Switch to:
Switch to:
See Also
Discover More
